hcvin4

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].

HCV-IN-47 ,with CAS No. 300543-56-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. HCV-IN-47 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

HCV-IN-46 (compound 6d) is an HCV inhibitor with an EC50 value of 3.717 μM, exhibiting antiviral activity.

HCV-IN-39 (Compound 18a) is a potent, orally active nucleoside inhibitor of hepatitis C virus (HCV), effective against the GT1a replicon (EC50: 0.259 μM), GT1b replicon (EC50: 0.434 μM), and GT1b CES1 replicon (EC50: 0.069 μM).

HCV-IN-41 (compound 4), a potent inhibitor of the hepatitis C virus (HCV), demonstrates exceptional inhibitory effectiveness across different genotypes, with EC 50 values of 0.006762 nM for genotype 1b, 5.183 nM for 2a, 1.365 nM for 3a, and 142.2 nM for 4a, respectively. It effectively reduces HCV RNA replication [1].

HCV-IN-43 (compound 2), an HCV NS5B protein inhibitor, efficiently inhibits HCV virus replication and is utilized in the study of HCV infection [1].

HCV-IN-44 (compound 28) is an inhibitor of the HCV NS5B protein, effective in suppressing HCV virus replication and useful for researching HCV infection [1].